{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-019030","form_type":"8-K","ticker":"MED","cik":"0000910329","company_name":"MEDIFAST INC","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.408379+00:00","generated_at":"2026-06-03T06:06:44.759316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Medifast posts 50% revenue decline to $174.7M in Q1; EPS $0.76 vs $3.67 YoY","bullets":["Revenue of $174.7M, down 49.9% YoY; net income $8.3M ($0.76 diluted EPS) vs $40.0M ($3.67) in Q1 2023.","Active earning OPTA VIA coaches fell 35.6% to 37,800; revenue per coach decreased to $4,623 from $5,945.","Gross margin improved to 72.8% from 70.6% on inventory efficiencies, but SG&A as % of revenue rose to 68.3% from 55.3%.","Q2 2024 revenue guidance $150-170M; diluted EPS $0.05-$0.40, excludes LifeMD collaboration costs and investment gains/losses.","Cash and investment securities $156.4M with zero debt; company pivoting to GLP-1 weight loss support via LifeMD partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-019030","json":"https://secwatch.observer/filing/0001628280-24-019030.json","markdown":"https://secwatch.observer/filing/0001628280-24-019030.md","text":"https://secwatch.observer/filing/0001628280-24-019030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910329/000162828024019030/0001628280-24-019030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910329/000162828024019030/med-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:06:44.759316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a37d7e808de0b07a8837a1e1b2a521996ff3e4e","claim":"MEDIFAST INC reported first quarter ended March 31, 2024 results: revenue $174.7 million, net income $8.3 million, EPS $0.76 per diluted share.","evidence_excerpt":"Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTA VIA®, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 • Revenue of $174.7 million, with revenue per active earning coach of $4,623 • Independent active earning OPTA VIA Coaches of 37,800 • Net income of $8.3 million (non-GAAP adjusted net income of $7.2 million) • Earnings per diluted share (\"EPS\") of $0.76 (non-GAAP adjusted EPS of $0.66)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828024019030/0001628280-24-019030-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$174.7 million"},{"label":"Net income","value":"$8.3 million"},{"label":"EPS","value":"$0.76 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}